Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.67 |
| ▸ | CLK1 | P49759 | 4/20 | 0.67 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.67 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8338532 | 0.86 | DYRK1A (0.76) | DYRK1ACLK1DYRK1BHSD17B1BCL2L1 | |
| SCHEMBL6001663 | 0.85 | CNR2 (0.51) | DYRK1ACLK1DYRK1BHSD17B1CNR1 | |
| SCHEMBL6001641 | 0.84 | POLB (0.50) | DYRK1ACLK1DYRK1BHSD17B1ALDH1A1 | |
| SCHEMBL20748215 | 0.80 | HSD17B1 (0.80) | DYRK1ACLK1DYRK1BHSD17B1BCL2L1 | |
| SCHEMBL23041059 | 0.79 | DYRK1A (0.70) | DYRK1ACLK1DYRK1BHSD17B1BCL2L1 | |
| SCHEMBL10516290 | 0.79 | DYRK1A (0.70) | DYRK1ACLK1DYRK1BHSD17B1BCL2L1 | |
| SCHEMBL657185 | 0.79 | DYRK1A (0.70) | DYRK1ACLK1DYRK1BHSD17B1BCL2L1 | |
| SCHEMBL23041047 | 0.79 | DYRK1A (0.70) | DYRK1ACLK1DYRK1BHSD17B1BCL2L1 | |
| SCHEMBL28162040 | 0.79 | DYRK1A (0.51) | DYRK1ACLK1DYRK1BHSD17B1BCL2L1 | |
| SCHEMBL5999605 | 0.79 | DYRK1A (0.59) | DYRK1ACLK1DYRK1BHSD17B1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. | 2019-08-29 | — | — | US | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20060142271-A1 | Novel lapacho compounds and methods of use thereof | MUNSTER, UNIVERSITY OF (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1551392-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004026253-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142271-A1 | Novel lapacho compounds and methods of use thereof | XIAP, PIN1, NQO1 | DYRK1A 3249/4885CLK1 1883/4885DYRK1B 3609/4885 |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | DYRK1A 2328/4885CLK1 2017/4885DYRK1B 2356/4885 |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, JAK2 | DYRK1A 2489/4885CLK1 1916/4885DYRK1B 2508/4885 |
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | STAT3, STAT1, JAK2 | DYRK1A 2715/4885CLK1 1802/4885DYRK1B 2758/4885 |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | DYRK1A 2328/4885CLK1 2017/4885DYRK1B 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.